Patients with MMR-deficient tumors could then undergo targeted next-generation-sequencing and methylation testing of their tumor tissue and/or, if family history or age criteria are suspicious, targeted next-generation sequencing of MMR genes in their germline (blood) samples. Here, MRC1 is linked to neoplasm.